Anika Therapeutics, Inc. reported a revenue of $29.6 million for the first quarter of 2026, marking a 13% increase from $26.2 million in the same period of 2025. The company's gross profit also rose significantly, reaching $19.0 million with a gross margin of 64%, compared to 56% in the prior year. This increase in revenue was primarily driven by higher sales from the Original Equipment Manufacturer (OEM) channel, particularly from Johnson & Johnson MedTech, and increased international sales of its osteoarthritis (OA) pain management products. However, the company recorded a net loss of $5.1 million, slightly higher than the $4.0 million loss reported in the first quarter of 2025.
Operating expenses for the quarter increased to $24.5 million, up from $19.0 million a year earlier, largely due to a rise in selling, general, and administrative expenses, which included a $3.3 million increase in stock-based compensation and $1.6 million in severance costs related to a restructuring initiative. Research and development expenses also grew by 11% to $6.7 million, reflecting increased investment in clinical studies for its Cingal product and other development projects. The company’s loss from continuing operations was $5.1 million, compared to a loss of $4.0 million in the same quarter last year.
Anika Therapeutics has undergone significant strategic changes, including the divestiture of its Arthrosurface and Parcus Medical businesses to focus on its OA Pain Management and Regenerative Solutions segments. The company is actively pursuing FDA approval for its Cingal product, which is designed to provide pain relief for OA patients. The company has made progress in addressing FDA requirements and is targeting a U.S. launch for Cingal, which could tap into a $1 billion market.
In terms of operational metrics, Anika's cash and cash equivalents decreased to $41.0 million as of March 31, 2026, down from $57.5 million at the end of 2025. The company reported cash used in operating activities of $4.8 million for the quarter, compared to $0.1 million in the same period last year. The increase in cash used was attributed to higher inventory purchases and accounts receivable due to increased sales activity. The company also repurchased $8.7 million worth of its common stock during the quarter as part of its ongoing share repurchase program.
Looking ahead, Anika Therapeutics aims to leverage its proprietary hyaluronic acid technology to drive growth in its target markets. The company plans to continue expanding its product offerings and pursuing strategic partnerships to enhance its market position. Despite the current losses, Anika's management remains optimistic about future revenue growth and the potential for profitability as it focuses on its core business areas.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. develops and manufactures hyaluronic acid (HA)-based medical products focused on osteoarthritis (OA) pain management and regenerative orthopedic solutions. Its key offerings include viscosupplements like Monovisc and Orthovisc, and regenerative products such as the Integrity Implant System and Hyalofast scaffold. Serving global markets through direct sales and distributor networks, Anika targets clinicians and surgeons with innovative, clinically supported therapies designed to improve patient outcomes in early intervention orthopedics.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.